Core Insights - The company Zhaoke Ophthalmology-B (06622) has received approval from the National Medical Products Administration (NMPA) for clinical trials of PAN-90806 eye drops for the treatment of wet age-related macular degeneration (wAMD) [1] - The company also announced the approval of its eye drops, Epiphenidine Hydrochloride, for the treatment of allergic conjunctivitis [2] Group 1: PAN-90806 Eye Drops - PAN-90806 is a novel anti-VEGF eye drop formulation designed for wAMD treatment, characterized by favorable physicochemical properties and intended for external use [1] - If approved as a maintenance therapy, PAN-90806 is expected to provide significant convenience and less invasive treatment options for patients, reducing the frequency of intravitreal injections associated with mainstream anti-VEGF therapies [1] - The anticipated use of PAN-90806 is projected to significantly decrease treatment interruptions, enhancing patient comfort, acceptance, convenience, and adherence to medical advice, thereby slowing disease progression [1] Group 2: Market Potential - wAMD is a leading cause of vision loss and blindness among individuals over 50 years old in China and globally [1] - According to Frost & Sullivan, the market size for wAMD drugs in China is expected to grow from USD 241.5 million in 2019 to approximately USD 3.5 billion by 2030, with a compound annual growth rate (CAGR) of 27.5% [1] Group 3: Epiphenidine Hydrochloride - Epiphenidine Hydrochloride is an antihistamine eye drop with dual mechanisms of action, effective for treating allergic conjunctivitis, particularly in acute patients, and is considered a first-line therapy in China [2] - The company's Epiphenidine Hydrochloride is a generic version of Elestat, developed by Allergan [2]
兆科眼科-B(06622)：国家药监局批准PAN-90806的新药临床试验申请及盐酸依匹斯汀滴眼液取得国家药监局的上市批准